NCT00811499 is a Phase 2 clinical trial of ARRY-371797, p38 inhibitor; oral in Ankylosing Spondylitis, sponsored by Pfizer.

Who is sponsoring NCT00811499?

NCT00811499 is sponsored by Pfizer.

What drugs are being tested in NCT00811499?

Interventions in NCT00811499: ARRY-371797, p38 inhibitor; oral, Placebo; oral, Placebo; oral.

What condition does NCT00811499 study?

NCT00811499 studies Ankylosing Spondylitis.

Is NCT00811499 still recruiting?

NCT00811499 is currently terminated. Last updated 19 October 2020.

Last reviewed 2020-10-19 · How we verify

NCT00811499

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis

Terminated Phase 2 Last updated 19 October 2020

What this trial tests

Phase 2 trial testing ARRY-371797, p38 inhibitor; oral in Ankylosing Spondylitis in 25 participants. Terminated before completion.

Timeline

16 December 2008

Primary endpoint
29 September 2009

29 September 2009

Quick facts

Lead sponsor	Pfizer
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	25
Start date	16 December 2008
Primary completion	29 September 2009
Estimated completion	29 September 2009
Sites	12 locations across Canada, United States

Drugs / interventions tested

ARRY-371797, p38 inhibitor; oral
Placebo; oral
Placebo; oral

Conditions studied

Ankylosing Spondylitis — all drugs for Ankylosing Spondylitis →

Sponsor

Pfizer — full company profile →

Who can join

18 and older, any sex, with Ankylosing Spondylitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 2 study, involving a 12-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-371797 (versus placebo) in treating ankylosing spondylitis, and to further evaluate the drug's safety. Approximately 130 patients from the US, Canada, Poland and Hungary will be enrolled in this study.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

An overview of mammalian p38 mitogen-activated protein kinases, central regulators of cell stress and receptor signaling.
Han J, Wu J, Silke J. · · 2020 · cited 103× · PMID 32612808 · DOI 10.12688/f1000research.22092.1
Atypical p38 Signaling, Activation, and Implications for Disease.
Burton JC, Antoniades W, Okalova J, Roos MM, et al · · 2021 · cited 52× · PMID 33920735 · DOI 10.3390/ijms22084183
The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials.
Denis A, Sztejkowski C, Arnaud L, Becker G, et al · · 2023 · cited 17× · PMID 37507210 · DOI 10.1136/rmdopen-2023-003279

Verify or expand the search:

Other trials of ARRY-371797, p38 inhibitor; oral

Trials testing the same drug.

NCT00790049 — A Safety Study of ARRY-371797 in Healthy Subjects · Phase 1 · completed
NCT00663767 — A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction · Phase 2 · completed
NCT00542035 — A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction · Phase 2 · completed

Other recruiting trials for Ankylosing Spondylitis

Currently open trials in the same condition.

NCT07510789 — Impact of Low Back Pain Phenotypes on Function and Quality of Life in Ankylosing Spondylitis · recruiting
NCT07261644 — A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) · Phase 3 · recruiting
NCT07390929 — Clinical Trial Study on the Improved New Method of Acupotomy for AS · NA · recruiting
NCT06905288 — Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea. · recruiting
NCT07166874 — The Impacts of Gluten-free Diet in Patients With Ankylosing Spondylitis · NA · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00811499 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 19 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00811499.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing